Six-monthly HIV drug, lenacapavir, reduced HIV incidence by 96 per cent in trial. Affordability and supply remain key hurdles for rollout.

Gilead Sciences and Merck presented Phase 2 results showing 94.2% viral suppression in HIV patients treated with islatravir and lenacapavir. Both weekly and daily treatments achieved comparable ...

PRNewswire/ -- "According to the latest BCC Research study, "The global ADCs market is showing a rapid growth trend, with growth rates of 36.5% and 40.7% ...

Fintel reports that on October 21, 2024, Leerink Partners upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from ...

With the latest insights and statistics from the biggest pharmaceutical and healthcare device manufacturers across the globe, ...

Leerink has upgraded Gilead Sciences (GILD) to outperform, citing the growth outlook for its PrEP medication lenacapavir for ...

The 1) Market is expected to reach a substantial USD 34.83 billion by 2033, according to a new report. This reflects a ...

The global kinase inhibitor in autoimmune diseases market is projected to grow steadily over the next decade, according to a ...

As you can see from the chart above the percentage of shares that are sold short for Gilead Sciences has declined since its ...

Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...

Eli Lilly is making a series of investments in China to support its manufacturing and R&D operations. Gilead Sciences has ...

Fintel reports that on October 17, 2024, Bernstein initiated coverage of Gilead Sciences (NasdaqGS:GILD) with a Outperform ...